Psychedelics
Spravato Sales Lead J&J Third Quarter Results
Johnson & Johnson has released its 3rd quarter results and once again Spravato sales have shown impressive growth.
The post Spravato Sales Lead J&J…
Johnson & Johnson has released its 3rd quarter results and once again Spravato sales have shown impressive growth.
With the industry and investors eagerly waiting to see what the commercial market for psychedelics will look like — we must look to Spravato for a real-world example of how psychedelic medicine might perform once receiving FDA approval. Although off-label ketamine is delivered in clinics or through at-home delivery, J&J’s Spravato (through its subsidiary Jannsen) us the only FDA-approved psychedelic to date.
Spravato, also known as esketamine, gained FDA approval in 2019 as a breakthrough treatment for individuals with treatment-resistant depression (esketamine is the s-enantiomer of ketamine). This was the first FDA approval of a psychedelic compound for therapeutic use in the United States.
After a few slow years and little sales news, this year we began to hear financial results on Spravato. As reported in J&J’s Q1 2023 results, Spravato sales in the 1st quarter of 2023 were $131 million — an impressive 87% increase from Q1 2022 to Q1 2023. These figures made the psychedelic the fastest-growing program in Janssen’s portfolio.
Now we’ve received 3rd quarter results and once again Spravato sales have logged the biggest % growth in J&J’s portfolio — a whopping 82% increase in sales compared to the 3rd quarter last year.
$182 million in revenue in the third quarter. Not bad. Especially considering that just a tiny fraction of doctors are educated on psychedelics and prescribing Spravato.
Just one data point. But definitely an encouraging one.
See this chart from Brom Rector of Empath Ventures on Spravato’s year-over-year growth.
JNJ's Spravato did $183mm in Q3 revenue
Strong case for the financial viability of psychedelic medicine
Source -> https://t.co/l9Zryyyr9m pic.twitter.com/vWMV7s0HUz
— brom (@therealbrom) October 17, 2023
The post Spravato Sales Lead J&J Third Quarter Results appeared first on Microdose.
ketamine psychedelic depression psychedelics investors fda-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness